Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX208 + trametinib
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HLX208 + trametinib is an investigational **combination therapy** of two small molecule inhibitors designed for the treatment of **BRAF V600E-mutant advanced solid tumors and neoplasms**. HLX208 is a novel BRAF V600E inhibitor developed by Shanghai Henlius Biotech, with a proprietary chemical structure and high bioavailability, currently in phase 1 clinical trials. Trametinib is a marketed MEK inhibitor that targets the MAPK/ERK signaling pathway downstream of BRAF, used to inhibit tumor cell proliferation. The combination aims to block consecutive steps in the MAPK pathway—BRAF and MEK—potentially improving efficacy and overcoming resistance seen with BRAF inhibitor monotherapy. Current clinical development includes adults with BRAF+ metastatic or recurrent advanced solid tumors who have failed standard treatments[1][4][7].
- Brand names
- HLX208 + trametinib
- Other names
- HLX208 + trametinibHLX208 (BRAF V600E inhibitor) and trametinib
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)BRAF V600E
Beyond the preview
Go deeper on HLX208 + trametinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX208 + trametinib.